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Abstract

Medicines can save lives only if they are safe, efficacious, of good quality and affordable.
The use of unsafe, substandard, ineffective and counterfeit drugs can be harmful to the
health of the users and the public. Governments have an obligation to ensure the safety,
efficacy and quality of the drugs available to the public by regulating the manufacturing
and distribution of drugs and by exercising legal power to control the proliferation of
unsafe counterfeit medicines. This article surveys the factual and legal issues surrounding
counterfeit drugs in three countries, namely Cambodia, Vietnam and Thailand, in order to
determine the magnitude and characteristics of the drug counterfeiting problem within the
Southeast Asian region.
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Combatting Counterfeit Drugs:
Case Studies of Cambodia, Vietnam, and Thailand
Jakkrit Kuanpoth*

Introduction
The people’s right to health includes the right of access to a reliable standard of healthcare and a
good quality drug product. Medicines can save lives only if they are safe, efficacious, of good
quality and affordable. The use of unsafe, substandard, ineffective and counterfeit drugs can be
harmful to the health of the users and the public. Governments have an obligation to ensure the
safety, efficacy and quality of the drugs available to the public, which can be done by: (1)
regulating the manufacture, export, import, storage, distribution, supply and sale of drugs, and
(2) exercising legal power to control the proliferation of unsafe counterfeit medicines. The
prevalence of drug counterfeiting in Southeast Asian countries, including Cambodia, Laos,
Myanmar, Thailand and Vietnam is evident, which poses a public health risk, contributes to poor
treatment outcomes and wastes precious public and private financial resources in those countries.
The drug counterfeiting problem in those countries is occurring with great frequency due to the
substantial profits that can be realised from such transactions. The increase in counterfeiting
may also be motivated by other factors, including the economic incentives provided by an
increasing volume of high cost drugs, ineffective drug regulation, weakness of law enforcement
and the ability to manufacture, transfer and distribute drugs from one country to another.1 This
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article surveys the factual and legal issues surrounding counterfeit drugs in three Southeast Asian
countries, namely Cambodia, Vietnam and Thailand, in order to determine the magnitude and
characteristics of the drug counterfeiting problem within the region. Part 1 examines the extent
of the problems in the countries surveyed. Part 2 discusses existing laws of Cambodia, Vietnam
and Thailand that regulate the distribution and marketing of medicines. This legal analysis will
examine whether or not the current legal framework of the three countries is adequate and
effective in dealing with counterfeit drugs. Part 3 examines the concept and definition of
counterfeit drugs in order to avoid variations in the legal interpretation and implementation. The
issues of law enforcement and border controls are surveyed in Parts 4 and 5 in order to detect the
problems of combatting counterfeit drugs in the three countries.

Extent of drug counterfeiting problems in Cambodia, Vietnam and Thailand

Drug counterfeiting is an illegal activity, which is hard to detect and investigate. It is hard to
know or even estimate the true extent of the problem. What is known is that it occurs in almost
all countries and is more prevalent in developing countries. Available information illustrates the
extent and seriousness of the problem, which persists despite national and regional efforts to
tackle it. According to the World Health Organization (WHO), it is estimated that about 10
percent of the drugs available worldwide may be counterfeit.2 According to the World Customs
Organization (WCO), the value of counterfeit drugs is estimated to be USD 200 billion per year.
The WCO reported that in 2013 alone more than half of 24,092 cases of seizures of intellectual
property infringing goods were related to illegal medicines.3 It was found that over 920 medical
products from all the main therapeutic categories, including medicines, vaccines and in vitro
diagnostics, have been found to be counterfeit drugs.4

While counterfeit drugs have been

reported in all regions of the world, the prevalence of drug counterfeiting in various countries
throughout Southeast Asia appears to be rising. The counterfeit drugs that have been found in
the region include antibiotics, anti-malarial agents, anti-tubercular drugs, anti-retroviral agents,
vitamins, painkillers, hormones, and steroids.5 Particularly, the quantities of available fake
artesunate, a drug for the treatment of multi-drug resistant Plasmodium falciparum malaria, are
strikingly high in the region and were found in Cambodia, Laos, Myanmar, Thailand and
Vietnam. According the 2001 survey, among 104 shop-bought samples taken from those five
countries, 30 samples (29%) was found to contain no artesunate and 39 samples (38%) were
counterfeit.6 A more recent study has shown similar results.7 Because of the high prevalence of
counterfeits, it is believed that Asia is the region most frequently linked to pharmaceutical crime
incidents, including drug counterfeiting.8

Cambodia, one of the three countries studied, shares borders with Thailand, Laos, and Vietnam.
Cambodia is, in fact, not a major producer of counterfeit drugs, but it suffers badly from
counterfeit and illicit medicines due to the rapid increase in recent years in the production of
counterfeit drugs in other Asian countries. The proliferation of counterfeit drugs in the country
can be attributable to the economic incentives provided by the increasing volumes of high cost
drugs, ineffective drug regulations, weaknesses of local law enforcement, the ability to import
drugs into vulnerable countries and corruption.9 A study undertaken by Rozendal on fake
antimalarial drugs in Cambodia found that patients and village heath providers preferred
counterfeit drugs because their prices were lower.10

As we can observe in similar patterns across Southeast Asia, the counterfeiting of drugs in
Cambodia usually appears in the form of finished pharmaceuticals, i.e. the final product taken by

the patient, rather than the counterfeiting of bulk drug ingredients. This is due to the country’s
lack of manufacturing capacity. Currently, there are only six (6) drug manufacturers throughout
Cambodia. Counterfeit drugs are usually not produced in Cambodia but are illegally imported
into the country.11 However, Cambodian Customs officials believe that a small number of
counterfeit drug products may be produced locally. During my field work in Cambodia, I had
discussions with the Cambodian authorities. They told me that they are becoming increasingly
concerned with the significant increase in the amounts of counterfeit drugs coming into the
country from China, India, Thailand, Vietnam and elsewhere in the region. Though the drug
officials are fully aware that most counterfeit drugs come from abroad, the challenges of
protecting against unsafe counterfeit drugs is difficult as there are several channels through
which drugs can be brought into the country. The lack of investigation and prosecution in the
countries where counterfeit drugs are produced makes it almost impossible to stop the
importation of drugs into Cambodia. Additionally, although the Cambodian Government and its
drug agency, i.e. the Department of Drug and Food (DDF), have recently adopted an integrated
plan for enforcing prohibitions against counterfeit drugs, the challenges still remain, including a
lack of financial and human resources, inadequate supplies of safe medicines and outdated
regulatory systems, resulting in many counterfeit drugs escaping detection until they reach the
retail consumer level.

In Cambodia, criminal activities related to drug counterfeiting have become an increasing
problem with many illegal drug outlets operating and selling drugs without licences from the
DDF. Drug outlets and pharmacy shops are the country’s most important distribution channels.
The drug outlets, many of which are wholesalers, purchase drug products directly from
manufacturers and importers and then sell those products directly to consumers. The number of

illegal drug outlets is larger than the outlets licensed by the DDF. While there are 1,014 regulated
drug outlets consisting of 393 pharmacies, 175 depot A, and 446 depot B, the number of illegal
outlets is estimated to be 2,461. Both licensed and unlicensed drug outlets and pharmacy shops
may knowingly or unknowingly distribute counterfeit drugs. However, the drug official I
interviewed believed that the volume of counterfeits sold by illegal outlets was much higher than
that supplied through the licensed outlets. The official also agrees that Cambodia needs tougher
regulations against illegal drug distributors.

In Vietnam, the number of counterfeit drugs is quite high. According to a survey undertaken by
the National Institute of Drug Quality Control of Vietnam, 7 percent of the 25,000 samples
collected from 20 provinces were found to be counterfeit.12 The counterfeit drugs, particularly
anti-malaria drugs, are prevalent in Vietnam. For example, 64 percent of artesunate drugs bought
in the country were found to be counterfeit.13 A report of the EU-Vietnam Business Network
(EVBN) confirms that Vietnam’s pharmaceutical market suffers from the proliferation of
counterfeit drugs and a lack of certified pharmacies and pharmacists.14

Counterfeiting of medicines is also a growing problem in Thailand. Although there are no
collected data on drug counterfeiting, counterfeit medications have been found in the Thai
market from time to time. The drug authority has discovered counterfeiting activities involving
both production and smuggling. It was reported that 11 percent of artesunate drugs taken from
shops in Thailand were found to be counterfeit.15 In 1989, a licensed manufacturer was found to
be producing unregistered antibiotics with little active ingredients. In 1998, the drug authority, in
collaboration with the police, arrested an unauthorised manufacturer who was illegally producing
counterfeit drugs. In 2001, two companies selling counterfeit Viagra medication were arrested

and subsequently prosecuted. In 2002, a drug store in Bangkok was charged for selling
counterfeit drugs. In 2003, a person who was smuggling fake Viagra into Thailand was arrested
at the airport.16 An investigation in 2015 by Al Jazeera showed that fake medicines are openly
being sold on the streets in Thailand.17

A counterfeit drug has better capacity to deceive, particularly if it is copied to make it look like
the original product. Samples of counterfeit drugs collected by the drug regulatory authorities in
Cambodia, Vietnam and Thailand show substantive similarities to the genuine products. Drug
inspectors in those countries admitted to me that it was difficult for them to detect whether a
product is counterfeit. This would be far more difficult for patients to detect whether the product
they are buying is of good quality. The prevalence of counterfeit drugs is due to the fact that such
drugs are easy to carry. The lack of investigation and prosecution in the countries where the
counterfeit drugs are produced makes it almost impossible to stop the smuggling and importing
of drugs from other countries. Cambodia and Vietnam have set up an inter-ministerial committee
on this issue, and Cambodia has adopted an integrated plan against the importation and
distribution of counterfeit drugs and has actively implemented it over the past few years. From
January 2009 to October 2011, the Cambodian Ministry of Health, in collaboration with the
WHO, initiated a project to contain and examine artemisinin-resistant Plasmodium falciparum
malaria.18 The inter-ministerial committee on counterfeit drugs started a campaign against illegal
drug outlets, reducing the number in Cambodia from 1,420 in 2009 to 87 in 2010.19

Legislation combating counterfeit drugs in Cambodia, Vietnam and Thailand

As in most countries, counterfeit drugs in the countries studied (i.e. Cambodia, Vietnam and
Thailand) pose potentially serious public health and safety concerns. However, there is no
specific law enacted to deal with this problem in any of the three countries. The control of drug
counterfeiting in these countries is under the national drug laws discussed below.

Cambodian law

As in most countries, counterfeit drugs in Cambodia pose potentially serious public health and
safety concerns, but no specific legislation has been passed to combat this threat. The regulation
of pharmaceuticals in Cambodia is under the national drug law called the “Management of
Pharmaceuticals Act (MPA)”, which was enacted in 1996 and was subsequently amended in
2007. The MPA comprises 15 articles, providing controls on manufacturing, the importation of
medicines, inspections, and law enforcement. The Act has the main aim of ensuring that
pharmaceutical products distributed in Cambodia are safe and effective and seeks to avoid an
unacceptable risk of counterfeit, adulterated, misbranded, substandard or expired drugs being
sold to the public.

The main articles used by law enforcement bodies are summarised below.

1) The DDF is authorised to issue Sub-decrees and Prakas (i.e. notifications) to regulate the
distribution and production of pharmaceuticals. The DDF can issue a license for the
establishment of a drug manufacturer, and for the importing, exporting, selling and
advertisement of drugs. All drug outlets are required to have a pharmacist or a health
professional who has acquired the appropriate certificate from the Ministry of Health
(MOH) (Articles 7 and 8).

2) Any person who (1) engages in any production, importation, exportation, advertising or
distribution of drugs without authorisation from MOH, (2) violates the procedures and
conditions for the production, importation, exportation and selling of drugs, and (3)
changes the location of the approved establishment without authorisation from the MOH,
shall be subject to a fine of KHR 1 million (Cambodian riel) and a suspension of such
activities for a period of one to three months in the discretion of the drug regulatory
authority (Article 10).
3) Any person who deliberately engages in producing, importing, exporting or distributing
(1) drugs containing addictive substances without authorisation, (2) counterfeit and
substandard drugs, or (3) expired drugs that affect the health or lives of the consumers,
shall be deemed guilty of a criminal offence and on conviction thereof, shall be punished
by a fine ranging from KHR 20 million to 50 million, or by imprisonment between five
and ten years, or by both said punishments, in the discretion of the court (Section 12).

However, the MPA seems to be ineffective against counterfeiting practices. It does not contain
any safeguard measures to deal with the importation of counterfeit drugs. Since drugs sold in
Cambodia are manufactured outside its borders, the lack of effective enforcement to combat the
importation of the counterfeit drugs that are flooded the Cambodian market is of major concern.
Certain mechanisms to help address some of the risks posed by counterfeit drugs must be
introduced. This includes increasing the criminal penalties for distribution of unapproved or
misbranded drugs. The law could also improve the regulatory process for imported drugs and
authorise the authorities to administratively detain imported drugs suspected to be counterfeit. A
clear definition of counterfeit drugs that is in line with the WHO definition must also be adopted.

Vietnamese law

In Vietnam, pharmaceutical legislation and regulation is in the form of a series of
complementary laws. Like its neighbours, Vietnam has no specific law dealing with the problem
of counterfeit drugs. The control of drug counterfeiting in Vietnam is under various laws,
including the following:
•

Criminal Act

•

Law on the People’s Health Protection

•

Law on Prevention of Public Health

•

Ordinance on Private Medical and Pharmaceutical Practices

•

Decree on Drugs for Prevention and Treatment of Human

•

Various regulations, including the Regulation on Management of Drug Quality,
the Regulation on Drug Sampling, and the Regulation on Drug Registration

The laws of Vietnam include provisions relating to manufacturing, importing, distribution,
marketing, labelling, dispensing, inspecting and law enforcement. This legislation and the
accompanying regulations have the identical aim of ensuring the quality and efficacy of the
pharmaceutical products sold to the public, and prohibiting counterfeit, adulterated, misbranded,
substandard, or expired drugs being sold to the public. For example, Article 29 of the Ordinance
on Private Medical and Pharmaceutical Practices prohibits individuals and legal entities from
selling counterfeit drugs. Article 157 of the Criminal Act provides criminal sanctions for those
dealing in counterfeit drugs. According to the provision, the criminal penalties for the offences of
producing, importing, exporting and distributing counterfeit drugs are two to seven years
imprisonment and a fine of between VND 5 million and 50 million (Vietnamese dong). The law

also authorises the drug regulatory authority to impose a suspension or revocation of the
practising licence of a health professional found producing or selling counterfeit drugs for a
period ranging from one to five years.

One of the regulatory authorities, the Drug Administration of Vietnam (DAV) under the Ministry
of Health, was established for administrative control. The DAV is authorised to regulate the
distribution and production of pharmaceuticals. It can issue a licence to run pharmaceutical
manufacturing establishment, or issue a licence to import, export, sell or advertise drugs. All
drug distributors and pharmacies are required to retain a pharmacist or a health professional who
has acquired the appropriate certificate from the authorities.

Under Vietnamese law, a drug retailing establishment, which is entitled to distribute drugs, must
obtain a good pharmacy practice (GPP) certificate from the Department of Health. The certificate
can only be issued to those who meet the required conditions regarding personnel and
infrastructure set out by the Health Department. The legal consequences for non-compliance will
result in the cancellation of the certificate and a fine ranging from VND 500,000 to VND 40
million. Under the law, the MOH is responsible for supervising distribution activities. Also, drug
establishments must be randomly inspected on a regular basis. However, I was told during my
interviews that licensed establishments are rarely inspected due to the MOH’s lack of qualified
inspectors. This inadequacy is a major contributing factor to the prevalence of unauthorised
distributors and unregistered products in Vietnam.

The drugs that are distributed in Vietnam must have marketing authorisation, which is issued by
the DAV, with some exceptions for drugs intended to be used for special purposes. Although the
relevant law of Vietnam contains provisions dealing with drug counterfeiting, there is still

weakness in the existing law. First, it provides weak penalties for drug counterfeiting, which are
simply not sufficient to deter the criminal element in the counterfeit drug trade. The penalty for
dealing with counterfeit drugs is two to seven years’ imprisonment, and then only if the
authorities are able to show that the offender has a specific intent to produce or distribute the
counterfeit drugs. In addition, Vietnamese law does not impose severe penalties for unlicensed
distributors or street vendors, which are generally the major channels of counterfeit drug
distribution. It also does not impose criminal charges against representatives of companies or
juristic persons who are involved in counterfeiting, thus allowing counterfeiters to escape
detection, arrest, and penal sanctions. Further, the law does not provide guidelines and checklists
to guide regulatory practice in handling counterfeit drugs.

Thai law

In Thailand the control of counterfeit drugs is under the Drug Act B.E. 2510. The regulation of
drugs in Thailand is administered by the Food and Drug Administration (FDA) of the Ministry of
Public Health. The distribution and importation of medicines requires an import and/or
manufacturing licence, which can be issued by the FDA. In addition, drugs to be distributed in
Thailand must also be registered with the Thai FDA. There are some exceptions under which
certain drugs do not require product registration. For example, a doctor may distribute medicines
directly to his or her patients without a licence. The Notification of the Ministry of Public No.
14, B.E. 2532, states that certain medicines imported into Thailand may be exempted from
product registration if they are used for research, analysis, exhibition or charitable purposes.
However, the right to import drugs without a licence is limited to certain agencies, including to a
government agency with duties encompassing the prevention and treatment of diseases, the Thai

Red Cross Society, and the Government Pharmaceutical Organisation. Any person who commits
a violation of the regulations is subject to administrative (i.e. cancellation of licence) and
criminal sanctions (i.e. imprisonment and fines).

Under the Drug Act B.E. 2510, the criminal penalties for the offences of producing, importing,
exporting, and distributing counterfeit drugs are three years to life imprisonment and a THB
10,000 to 50,000 (Thai baht) fine for producing counterfeit drugs, and a jail term of one to
twenty years and a THB 2,000 to 10,000 fine for selling, importing or ordering counterfeit drugs.
The law also provides for the suspension or revocation of the practising licence of those found
producing or selling counterfeit drugs. The Drug Act B.E. 2510 provides criminal sanctions
against distributing unregistered drugs. The sanction for this offence, according to Thai law, is
three years’ imprisonment and a THB 5,000 fine.

Comparatively, the main features of the pharmaceutical laws of the three countries are similar,
which can be summarised as follows:
•

The laws of the three countries provide controls on manufacturing, importation,
inspections and law enforcement. This legislation and the complementary
regulations have the identical aim of ensuring that pharmaceutical products in the
country are safe and effective and avoiding an unacceptable risk of counterfeit,
adulterated, misbranded, substandard or expired drugs being sold to the public.

•

In those countries, the drug regulatory authorities are authorised to regulate the
distribution and production of pharmaceuticals. They can issue a licence for
establishing a drug manufacturer, importing, exporting, selling and advertising
drugs. All drug distributors and pharmacies are required to retain a pharmacist or

a health professional who has acquired the appropriate certificate from the
authorities.
•

The laws of the three countries provide administrative and criminal sanctions for
those dealing in counterfeit drugs. The criminal penalties for the offences of
producing, importing, exporting and distributing counterfeit drugs include: (1) in
Cambodia a fine from KHR 20 million to 50 million or imprisonment between
five and 10 ten years; (2) in Vietnam two to seven years’ imprisonment; and (3) in
Thailand three years to life imprisonment and a THB 10,000 to 50,000 fine for
producing counterfeit drugs, in addition to a jail term of one to twenty years and a
THB 2,000 to 10,000 fine for selling, importing or ordering counterfeit drugs. The
laws of the three countries also provide for the suspension or revocation of the
practising licence of those found producing or selling counterfeit drugs.

•

The laws of Cambodia and Thailand provide criminal sanctions against the
distribution of unregistered drugs, but the penalties for this offence are not severe
enough. For example, those who produce and sell unregistered drugs are subject
to a fine of KHR 10 million and one to three months imprisonment under
Cambodian law. The sanctions for the same offence, according to Thai law, are
three years’ imprisonment and a THB 5,000 fine. No criminal sanctions are
imposed on the person who produces and sells unregistered drugs under
Vietnamese law.

Although the relevant laws of Cambodia, Vietnam and Thailand contain provisions dealing with
drug counterfeiting, there is still weakness in the existing law. For example, it provides weak

penalties for drug counterfeiting, particularly in the cases of Cambodia and Vietnam. In addition,
the laws of the three countries do not impose severe penalties for unlicensed distributors, which
are generally the major channels of counterfeit drug distribution. They also do not impose
criminal charges against representatives of companies or juristic persons, which allows
counterfeiters to escape detection, arrest and penal sanctions. The laws of the three countries do
not provide guidelines or checklists to guide regulatory practice in handling counterfeit drugs.
The inadequacy of the laws and regulations leads to the prevalence of unauthorised distributors
and unregistered products. The respective governments may need to enact special national
legislation on counterfeit drugs in order to improve the regulatory process and to stiffen penalties
for those who engage in counterfeiting.

Definition of counterfeit drugs

Counterfeit drugs are defined differently in different countries. The absence of a universally
accepted definition makes collaboration between countries very difficult. Differentiation of the
definition of counterfeit drugs under the laws of different countries can lead to variations in the
legal interpretation and implementation to combat or prevent drug counterfeiting. To implement
effective countermeasures against counterfeit drugs, a unified definition under the laws of each
of the affected countries is required. The World Health Organization (WHO) has formulated
such a definition as follows:
“A medicine, which is deliberately and fraudulently mislabelled with respect to identity
and/or source. Counterfeiting can apply to both branded and generic products and
counterfeit products may include products with the correct ingredients or with the wrong

ingredients, without active ingredients, with insufficient active ingredients or with fake
packaging.”20

The WHO definition refers to counterfeit drugs as those produced with an intention to mislabel a
product. The WHO definition also differentiates counterfeit drugs from substandard drugs.
Substandard drugs are genuine medicinal products that do not meet quality specifications set for
them by national standards.21 The term ‘substandard’ is used to describe the quality status of
genuine drugs produced by legitimate manufacturers. Normally, for each medicinal product that
a manufacturer produces it must meet the quality standards or specifications set by national drug
authorities. If a drug, upon laboratory testing in accordance with the specifications with which it
claims to comply, fails to meet such specifications, then it is classified as a substandard drug.

Cambodian law

Clause 1 of the Official Notification on the Prohibition for Selling Counterfeit Drugs 2003,
which was enacted to implement the MPA, divides counterfeit drugs into four categories: (1)
drugs that are deliberately produced with no or insufficient active ingredients; (2) drugs that are
deliberately produced with incorrect active ingredients, according to defined pharmacopoeias
standards; (3) drugs that are deliberately and fraudulently mislabelled with respect to identity or
source; and (4) drugs that are repacked, produced or imported without a licence.

Vietnamese law

The Decree on Drugs for Prevention and Treatment of Humans defines counterfeit drugs as
“products deliberately and fraudulently manufactured without or with very low content of active

ingredients, containing incorrect ingredients, or with packaging similar to the drugs of other
producers.” Vietnam’s definition is in line with that of the WHO’s definition.

Thai law
Section 73 of the Drug Act B.E. 2510 defines counterfeit drugs as “(1) a drug or substance that is
wholly or partly an imitation of a genuine drug; (2) a drug that shows the name of another drug,
or an expiry date that is false; (3) a drug that shows a name or mark of a producer, or the false
location of the producer; (4) a drug that falsely shows that it is in accordance with a formula that
has been registered; and (5) a drug produced with active substances for which the quantity or
strength is lower than the minimum or higher than the maximum standards prescribed in the
registered formula by more than twenty percent.” This definition is obviously different from the
WHO’s definition, as it provides a wider definition of counterfeit drugs, covering substandard
drugs. Substandard drugs, i.e. drugs produced with active substances for which the quantity or
strength is lower than the minimum or higher than the maximum standards prescribed in the
registered formula by more than twenty percent, are regarded as counterfeit drugs under Thai
law.

The following provides examples and a comparison of counterfeit pharmaceutical products,
according to the WHO definition and the laws of the three countries:22

Drugs
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fake packaging + correct quantity of

counterfeit

counterfeit

counterfeit
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counterfeit

counterfeit

fake

active

counterfeit

counterfeit

counterfeit
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counterfeit

counterfeit

counterfeit

counterfeit

counterfeit
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packaging
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quantity or
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20% higher or
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counterfeit
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counterfeit
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counterfeit

counterfeit

counterfeit, if

(deliberate)
genuine

packaging

+

incorrect

quantity of ingredients (deliberate)

quantity or
strength of
ingredients is
20% higher or
lower than the
registered
formula

genuine
quantity

packaging
of

+

incorrect

ingredients

(not

substandard

substandard

substandard

counterfeit, if
quantity or

deliberate)

strength of
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registered
formula

unregistered drugs

not counterfeit

counterfeit

not

not counterfeit,

counterfeit

unless with fake
packaging

genuine packaging + correct quantity

genuine

genuine

genuine

genuine

of ingredients

While Vietnam’s definition is in line with that of the WHO definition, the Cambodian and Thai
legislation provides a different definition for counterfeit drugs. The definition under Cambodian
law, unlike that of the WHO definition, regards unregistered drugs as counterfeit drugs. Thai law
provides a wider definition covering substandard drugs (i.e. drugs produced with active
substances for which the quantity or strength is lower than the minimum or higher than the
maximum standards prescribed in the registered formula by more than twenty percent).

Law implementation and enforcement
Counterfeiting is generally difficult to detect, investigate and quantify. However, it is especially
difficult to know the true extent of the problem, due to the lack of investigative efforts and
recorded figures. It is widely believed that drug counterfeiting is widespread and has generated
severe adverse effects on the health and livelihoods of the people in the three countries under

discussion. The high prevalence of counterfeit drugs in this region can be mainly contributable to
(1) absence of or weak anti-counterfeiting laws; and (2) weak or insufficient law enforcement.

Cambodia

The only way the counterfeiting problem in Cambodia can be solved is to strengthen the drug
regulatory authority. This in turn needs strong government resolve and commitment to provide
adequate human, financial and other resources, appropriate infrastructure and legal power to
enforce drug regulation. Unfortunately, like many other developing countries, the existence of
drug counterfeiting in Cambodia does not seem to draw much oversight from the government.
The authority to bring alleged violators of pharmaceutical law and regulations to court resides in
the DDF. The DDF derives its authority from the MPA and is given the power to enforce the
law. As is the case with most Cambodian government entities, the DDF suffers badly from
organizational shortcomings. A senior Cambodian government official told me that he wanted to
combat trafficking and distribution. However, several factors constrain any sustained advance in
effective law enforcement, including a lack of requisite funding and adequate resources to
support the law enforcement mission, an acute shortage of trained personnel, lack of basic
training in law enforcement techniques and drug law enforcement measures, high levels of
official corruption, and lack of collaboration between law enforcement bodies.

Regarding the licenced drug outlets, the DDF has sole authority to implement the drug law. It
can grant cease and desist orders, and penalties for violations of cease and desist orders, if it
finds that any licenced drug outlets have violated the law, including the selling of counterfeit
drugs. However, such authority has not been taken seriously. Though the law stipulates that the
licence of a drug outlet found to be violating the law shall be suspended for one to three months,

the suspended drug outlets can request for a pardon from the MOH. In practice, once a request
for a pardon is submitted to the MOH, the pardon is granted almost automatically. This partly
explains why the measure aimed at regulating drug outlets is ineffective to help combat the
counterfeiting problem.

The DDF has exclusive authority over the enforcement of the law against any authorised outlets
found violating drug laws and shares authority with other regulatory agencies, including
municipality authorities and the Ministry of Interior, for enforcing the law against those outlets
operating without a licence. However, the DDF has no power to collect the evidence and
information necessary for their enforcement of the drug law against the illegal outlets.
Cooperation with the police, the local authority and the judiciary is required to bring criminal
charges against those operating without a license. A criminal action can be initiated by the drug
regulatory authority, but a raid at an illegal drug outlet can only be carried out in the presence of
representatives of the four law enforcement agencies, i.e. the MOH, the National Police Bureau,
the municipality and the court. A successful raid will lead to the arrest of the offender and
seizure of the counterfeit drugs. The offender is then prosecuted in the court.

Cooperation between different authorities to close down all illegal drug outlets, which are the
major suppliers of counterfeit drugs, suffers from significant gaps in drug law enforcement.
Procedural obstacles exist between such enforcement authorities. As a result, there have been
few court cases relating to drug law. I was informed that in the past ten years 32 operators of
illegal outlets were arrested and prosecuted. Only half of those were convicted, and the same
number of outlets received court orders to close down. No doubt, the relatively small number of
illegal drug outlets closed down had virtually no effect on the scope of the problem.

The unsuccessful litigation against the illegal outlets can be explained by the fact that the courts
did not accept evidence submitted by the regulatory authority, claiming that such evidence had
been wrongfully obtained. In addition, there is a high burden of proof on the drug authority in
criminal proceedings. It has to be shown that the defendant is guilty beyond reasonable doubt.
This high burden of proof is especially difficult to overcome when trying to prove that the
defendant knew, or had reason to believe, that he was selling counterfeit drugs. Attempts have
been made by government bodies to cooperate in investigations, inspections and acquisition of
evidence. The MOH is currently considering proposing setting up of an inter-ministerial
committee concerning counterfeit drugs, which should lay the groundwork for judicial and law
enforcement cooperation among different authorities. Since cooperation between the DDF, the
police, Customs, and the judiciary is rather weak, it seems necessary that inter-sectoral
cooperation between regulatory authorities must be urgently undertaken for effective control of
the national drug market and enforcement of drug legislation. When such cooperation is delayed
or ineffective, counterfeiters will continue to escape detection, arrest and penal sanctions.

Vietnam

While interviewing a Vietnamese official, I was informed that the Government has taken serious
action against drug counterfeiting. It has introduced several measures to ensure the safety,
efficacy and quality of the medicines available to the public, including the promulgation of the
Law on Protection of People’s Health in 1989, the adoption of the National Drug Policy in 1996,
the setting up of the inter-ministerial committee on counterfeit drugs, and other courses of action.
The new law on Pharmacy regulation was approved by the National Assembly of Vietnam on 4
June 2016, which will take effect in late 2017 and will improve the health care system of

Vietnam. The government has also attempted to ensure that all 34,300 pharmacies operating in
the country are licenced and regularly inspected. However, the officials admitted that attempts to
implement and enforce the law have been constrained by several factors, including an acute
shortage of trained personnel, lack of adequate resources and inspection capacity, and lack of
collaboration between law enforcement bodies.

As in Cambodia and Thailand, the Vietnamese drug regulatory authority has exclusive power
over the enforcement of the drug laws against any authorised pharmaceutical distributors found
violating those laws.

The Government established an inter-ministerial committee against

counterfeit drugs, which laid the groundwork for judicial and law enforcement cooperation
among different authorities. It is believed that the establishment of that committee has improved
the enforcement of the law against counterfeit drugs and helped to reduce the current number of
counterfeit drugs to 0.03 percent.

Thailand

Thailand considers the problem of drug counterfeiting a priority. A special task force to combat
counterfeit drugs was established under the Drug Control Division of the FDA. However, the
shortage of personnel is the major obstacle to implementing and enforcing the law against
counterfeit drugs, especially in remote areas. Apart from the problems mentioned above, the
three countries also share a common problem of their respective drug authorities’ insufficient
power to carry out inspections. Ineffective or weak drug inspections have promoted smuggling
operations and the illegal distribution of drugs, which has led to the proliferation of counterfeit
drugs on the national market. It seems necessary that the drug law be amended to give strong
legal powers to drug inspectors to conduct inspections at all drug outlets, ports and airports.

Routine sample inspections of imported drugs, including mandatory inspections, will have to be
clearly delineated under the new law. Empowering the inspectors will have a strong impact on
the legal and illegal drug markets, but the law must regard drug-inspection fraud as a criminal
offence so that the government can take serious action against the wrongdoers. Like Cambodia
and Vietnam, Thailand’s drug authority is not presently equipped to carry out regular
inspections. The enforcement of the drug law also requires collaboration between various
agencies in order to bring criminal charges against manufacturers and distributors operating
against the law. However, unlike Cambodia and Vietnam, the Thai government has no plans to
establish an inter-ministerial committee against counterfeit drugs, as the Government does not
consider the lack of collaboration problem to be an issue.

However, it may be suggested that inter-sectoral collaboration is essential in the battle against
drug counterfeiting. Cooperation among not only regulatory authorities but also between the
government and the private sectors is required and should be urgently undertaken for effective
control of the national drug market and enforcement of drug legislation. Effective collaboration
between government authorities, industry and non-governmental bodies would help to track
counterfeit drugs and identify counterfeiters. In addition, cooperation in some matters with
foreign counterparts can result in greater efficiency and consistency in law enforcement.

Border controls
Though the countries’ regulatory authorities are fully aware that the majority of counterfeit drugs
come from abroad, the challenge of protecting the public against unsafe counterfeit drugs is
difficult because there are several channels through which drugs can be transported across the

borders. Since the counterfeiting of drugs has now become a regional issue affecting all countries
in the Southeast Asian region, an effective regional collaboration, similar to the one related to
narcotic drugs, is desirable. The respective governments also need to tighten border controls to
fight against the smuggling of counterfeit medicines.

Cambodia

Customs officers have power to inspect and seize counterfeit drugs at the borders. However, the
country’s main international airport, Pochentong, and its regional airport in Siem Reap, suffer
from lax Customs and immigration controls. Customs controls in both airports are rudimentary.
The Customs authority told me that random inspections are carried out to prove the validity of an
importer’s import licence, registration number and the expiry date of drugs, but so far, no illegal
imported drugs have been seized and no smugglers have been arrested. The DDF used to have
drug inspectors stationed at the airports and along key transit routes near Cambodia’s borders
with Vietnam and Thailand, but the crackdown at the borders was discontinued for two reasons:
(1) lack of manpower, capacity and funding to inspect imported drugs at the borders, and (2) to
support the government policy of promoting free trade with neighbouring countries. No doubt,
the inefficiency of law enforcement at the borders has led to a flood of unauthorised drugs into
Cambodia.

Ineffective or weak drug inspections have promoted smuggling and the illegal distribution of
drugs, which has led to the proliferation of counterfeit drugs on national market. It seems
necessary that the drug law be amended to give strong legal powers to drug inspectors to conduct

inspections at all drug outlets, ports and airports. Routine sample inspections of imported drugs,
including mandatory inspections, will have to be clearly delineated under the new law.
Cambodia may wish to revive its border inspection policy for counterfeit drugs. Customs
officers, together with drug inspectors, should be required to work closely together and to carry
out reasonable surveillance on imported goods, including the authority to issue an order for
seizure of drugs found to be counterfeit.

Vietnam

The DAV does not have its officials stationed at the borders. Customs has the sole authority to
control the drugs imported into the country. In practice, Customs officials attempt to inspect all
drugs imported into the country, but the inspection can only be carried out to ensure that the
imported drugs comply with the import requirements, such as having a proper licence,
registration number and correct specifications, as stipulated in the importation documents. There
is no quality checking of the imported drugs at the borders but random quality testing is carried
out at various warehouses. The officials admitted that the smuggling of counterfeit drugs is not
easy to detect due to Vietnam’s long borders with its neighbouring countries.

Thailand

Thailand allows pharmaceuticals to be imported into the country through certain checkpoints.
There are five control points through which the importation of raw materials used for
pharmaceutical purposes can be made.

There are 24 control points through which the

importation of finished products is allowed. Drugs imported through these transit routes are
inspected by FDA and Customs officials. The FDA has recently conducted quality testing of

imported drugs at Suvarnabhumi Airport. Counterfeit drugs have been found at those border
checkpoints from time to time. For example, Customs authorities in Thailand seized 75 kg of
diazepam trafficked in 2008, and in the same year, 192 kg of pharmaceutical preparations
containing pseudoephedrine were seized at the airport.23

The three countries studied share the same problems in controlling counterfeit drugs at their
borders. The main problem concerns the lack of manpower, capacity and funding to inspect
imported drugs. The inefficiency of law enforcement at the borders has led to a flood of
unauthorised drugs into these three countries. It may be suggested that all countries in the region
should increase the frequency of their respective border inspections for counterfeit drugs.
Customs officials and drug inspectors must work closely together and engage in the active
exchange of information and intelligence regarding counterfeit drugs. They should be required to
perform reasonable surveillance on imported medicinal goods and to issue an order to seize those
drugs found to be counterfeit.

Conclusion

Counterfeiting of drugs poses potentially serious public health and safety concerns. It affects not
only patients and innocent users but also the general public, and deserves more attention from all
governments. The problem has now become a regional issue affecting almost every country in
Southeast Asia. In order to solve the problem effectively, the following actions should be
considered:

(1) The national drug laws in the countries facing the counterfeit drug problem should be
revised and the following should be incorporated into those revisions:
•

The law should introduce a clear and wide-ranging definition of counterfeit
drugs. The definition should include drugs prohibited by official orders, expired
drugs, unregistered drugs, and drugs that do not reflect their actual efficacy (i.e.
substandard drugs).

•

The law should require the drug regulatory authorities to establish an extensive
regulatory framework to ensure that counterfeit pharmaceuticals will not be
imported and distributed in the market.

•

The law should introduce safeguards into the drug importation and distribution
system to provide assurances, through paper records, of the true source(s) and
distribution history of a drug. The offender may be ordered to disclose to the
regulatory authorities the names and addresses of his or her suppliers or
customers.

•

The law should strengthen the authority granted to drug inspectors to conduct
inspections. The officials of the drug regulatory authorities, who are designated as
law enforcers, should be able to file a motion with the court for a search warrant
in order to conduct a thorough investigation. This will somewhat alleviate the
delay and breach of secrecy in the search.

•

The law should observe the potential deterrence and other effects of stiffer
penalties on those found guilty of drug counterfeiting. The higher penalties are
required as the current penalties for some offences are not severe enough, such as
weak penalties for the operation of a pharmacy without a licence.

•

Where the criminal activities related to counterfeit drugs are committed by a legal
entity, the law should presume that all the members and managing directors of the
legal entity are accomplices to the offence and subject to the liability prescribed
for such offence.

(2) Once the revised law is adopted, the drug authorities and other relevant agencies must be
committed to implementing an aggressive enforcement strategy to combat counterfeit
drugs. The absence of legislation and deterrent sanctions will continue to encourage
counterfeiters since there is no fear of being apprehended and prosecuted.
(3) Drug production and distribution will have to be more aggressively managed.
(4) The drug regulatory authorities should be strengthened sufficiently to play the central
coordinating role in order to initiate more effective measures against drug counterfeiting.
Adequate manpower and funding must be provided to the drug authorities to inspect
producers, importers and distributors at the rate required to maintain drug quality.
(5) Large-scale and long-term international aid, including capacity building assistance and
law-enforcement aid, should be provided by the relevant international agencies to help
countries curb the distribution and trafficking of counterfeit drugs.
(6) The governments of all countries should run public education campaigns to educate
consumers about the steps they can take to minimise the risks associated with counterfeit
drugs. It should also educate consumers about what to look for, and what to do, if they
suspect they have received a counterfeit drug.
(7) Cooperation with private parties should be undertaken.

It would be prudent to

implement any strategic initiatives requiring the cooperation of manufacturers,

distributors, and retailers to track drugs through the marketplace, identify counterfeit
drugs, and notify the drug regulatory authorities of any suspected counterfeit drugs.
(8) Countries should improve coordination among their state agencies, including the drug
regulatory authority, Customs, the municipality, the police, and the judiciary.

The

national drug regulatory authority and other law enforcement agencies should also
engage in the exchange of information regarding counterfeit drugs. This collaboration
should also be undertaken with other interested parties, including foreign drug authorities
and international organisations, such as the WHO and Interpol.
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